Gaetana Porcelli

Dr. Gaetana Porcelli


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
MIMelania Lo Iacono
Melania Lo Iacono
CMChiara Modica
Chiara Modica
GPGaetana Porcelli
Gaetana Porcelli
OBOrnella Roberta Brancato
Ornella Roberta Brancato
Giampaolo MuratoreGiampaolo Muratore
Giampaolo Muratore
GSGiorgio Stassi
Giorgio Stassi
The tumor microenvironment (TME) plays a key role in promoting and sustaining cancer growth. Adipose tissue (AT), due to its anatomical distribution, is a prevalent component of TME, and contributes to cancer development and progression. Cancer-associated adipocytes (CAAs), reprogrammed by cancer stem cells (CSCs), drive cancer progression by releasing metabolites and inflammatory adipokines. In this review, we highlight the mechanisms underlying the bidirectional crosstalk among CAAs, CSCs, and stromal cells. Moreover, we focus on the recent advances in the therapeutic targeting of adipocyte-released factors as an innovative strategy to counteract cancer progression.

28 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Miriam GaggianesiMiriam Gaggianesi
Miriam Gaggianesi
LMLaura Rosa Mangiapane
Laura Rosa Mangiapane
CMChiara Modica
Chiara Modica
VPVincenzo Pantina
Vincenzo Pantina
GPGaetana Porcelli
Gaetana Porcelli
GSGiorgio Stassi
Giorgio Stassi
Despite advances in the curative approach, the survival rate of advanced colorectal cancer (CRC) patients is still poor, which is likely due to the emergence of cancer cell clones resistant to the available therapeutic options. We have already shown that CD44v6-positive CRC stem cells (CR-CSCs) are refractory toward standard anti-tumor therapeutic agents due to the activation of the PI3K pathway together with high HER2 expression levels. Tumor microenvironmental cytokines confer resistance to CR-CSCs against HER2/PI3K targeting by enhancing activation of the MAPK pathway. Here, we show that the CSC compartment, spared by BRAF inhibitor-based targeted therapy, is associated with increased expression levels of CD44v6 and Myc and retains boosted clonogenic activity along with residual tumorigenic potential. Inhibition of Myc transcription, downstream of the MAPK cascade components, and PI3K pathway activity was able to overcome the protective effects of microenvironmental cytokines, affecting the survival and the clonogenic activity of CR-CSCs, regardless of their mutational background. Likewise, the double targeting induced stabilization of mouse tumor avatars. Altogether, these data outline the rationale for dual kinase targeting of CR-CSCs to prevent their adaptive response, which would lead to disease progression.

Verified
Journal Article
Open access
PDF file
MTMaria Testa
Maria Testa
Miriam GaggianesiMiriam Gaggianesi
Miriam Gaggianesi
CDCaterina D’Accardo
Caterina D’Accardo
GPGaetana Porcelli
Gaetana Porcelli
ATAlice Turdo
Alice Turdo
MTMatilde Todaro
Matilde Todaro
In light of the emerging breakthroughs in cancer biology, drug discovery, and personalized medicine, Tumor-on-Chip (ToC) platforms have become pivotal tools in current biomedical research. This study introduced a novel rapid prototyping approach for the fabrication of a ToC device using laser-patterned poly(methyl methacrylate) (PMMA) layers integrated with a polylactic acid (PLA) electrospun scaffold, enabling dynamic drug delivery and the assessment of therapeutic efficacy in cancer cells. Traditional drug screening methods, such as conventional cell cultures, mimic certain aspects of cancer progression but fail to capture critical features of the tumor microenvironment (TME). While animal models offer a closer approximation of tumor complexity, they are limited in their ability to predict human drug responses. Here, we evaluated the ability of our ToC device to recapitulate the interactions between cancer and TME cells and its efficacy in evaluating the drug response of breast cancer cells. The functional design of the proposed ToC system offered substantial potential for a wide range of applications in cancer research, significantly accelerating the preclinical assessment of new therapeutic agents.